HUTCHMED Announces Preclinical Data for HMPL-A251 at AACR-NCI-EORTC Conference

HUTCHMED (China) Limited has announced preclinical data for HMPL-A251, a first-in-class PI3K/AKT/mTOR-HER2 Antibody-Targeted Therapy Conjugate (ATTC), at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. HMPL-A251 is designed to leverage the synergy between HER2 targeting and PAM pathway inhibition, addressing limitations of traditional toxin-based antibody-drug conjugates (ADCs) and standalone PAM inhibitors. The preclinical data showed robust antitumor activity with synergistic and bystander killing effects. HMPL-A251 demonstrated superior anti-tumor efficacy and tolerability compared to the naked antibody and payload administered together. The company plans to initiate global clinical trials for HMPL-A251 by the end of 2025, followed by multiple global Investigational New Drug (IND) filings for more ATTC candidates in 2026.